Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022
Clément Garnier(Inserm), Joëlle Micallef(Assistance Publique Hôpitaux de Marseille), Gaëtan Gentile, Clémence Lacroix(Inserm), Élisabeth Jouve(Inserm), Maryse Lapeyre‐Mestre(Université Fédérale de Toulouse Midi-Pyrénées), Thomas Soeiro(Inserm)
Cited by 8
Related Papers
French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic
|European Annals of Otorhinolaryngology Head and Neck Diseases|2020|76
Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database
|Journal of the Neurological Sciences|2019|60
Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions
|Clinical Pharmacology & Therapeutics|2021|48
Non-targeted screening for novel psychoactive substances among agitated emergency department patients
|Clinical Toxicology|2016|42